Published in Mol Cell on May 01, 1999
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling. Cell (2006) 10.06
MMDB: Entrez's 3D-structure database. Nucleic Acids Res (2003) 6.14
Structural bioinformatics-based design of selective, irreversible kinase inhibitors. Science (2005) 5.53
Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia. Blood (2008) 3.89
Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol (2008) 3.84
A Src-like inactive conformation in the abl tyrosine kinase domain. PLoS Biol (2006) 3.40
Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest (2000) 2.90
ErbB receptors: from oncogenes to targeted cancer therapies. J Clin Invest (2007) 2.78
Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol Cell (2011) 2.35
An unbiased cell morphology-based screen for new, biologically active small molecules. PLoS Biol (2005) 2.11
Specific Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat Chem Biol (2010) 1.94
Multidomain assembled states of Hck tyrosine kinase in solution. Proc Natl Acad Sci U S A (2010) 1.79
Mapping the conformational transition in Src activation by cumulating the information from multiple molecular dynamics trajectories. Proc Natl Acad Sci U S A (2009) 1.70
Structural basis for the recognition of c-Src by its inactivator Csk. Cell (2008) 1.66
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res (2009) 1.64
HIV-1 Nef selectively activates Src family kinases Hck, Lyn, and c-Src through direct SH3 domain interaction. J Biol Chem (2006) 1.51
Two distinct phosphorylation pathways have additive effects on Abl family kinase activation. Mol Cell Biol (2003) 1.50
Structural analysis of the EGFR/HER3 heterodimer reveals the molecular basis for activating HER3 mutations. Sci Signal (2014) 1.49
Conformational disturbance in Abl kinase upon mutation and deregulation. Proc Natl Acad Sci U S A (2009) 1.47
Src kinase conformational activation: thermodynamics, pathways, and mechanisms. PLoS Comput Biol (2008) 1.43
Small molecule recognition of c-Src via the Imatinib-binding conformation. Chem Biol (2008) 1.41
Src kinase activation: A switched electrostatic network. Protein Sci (2006) 1.40
Visualization of macromolecular structures. Nat Methods (2010) 1.34
An electrostatic network and long-range regulation of Src kinases. Protein Sci (2008) 1.30
Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs (2011) 1.29
Ras-dependent regulation of c-Jun phosphorylation is mediated by the Ral guanine nucleotide exchange factor-Ral pathway. Mol Cell Biol (2000) 1.24
Competing protein:protein interactions are proposed to control the biological switch of the E coli biotin repressor. Protein Sci (2001) 1.21
On the importance of a funneled energy landscape for the assembly and regulation of multidomain Src tyrosine kinases. Proc Natl Acad Sci U S A (2007) 1.21
Determinants of substrate recognition in nonreceptor tyrosine kinases. Acc Chem Res (2003) 1.19
Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compounds. ACS Chem Biol (2009) 1.18
An examination of dynamics crosstalk between SH2 and SH3 domains by hydrogen/deuterium exchange and mass spectrometry. Protein Sci (2005) 1.17
Allosteric loss-of-function mutations in HIV-1 Nef from a long-term non-progressor. J Mol Biol (2007) 1.12
Active Src elevates the expression of beta-catenin by enhancement of cap-dependent translation. Mol Cell Biol (2005) 1.12
Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner. J Biol Chem (2010) 1.08
The ErbB kinase domain: structural perspectives into kinase activation and inhibition. Exp Cell Res (2008) 1.08
Flexibility and charge asymmetry in the activation loop of Src tyrosine kinases. Proteins (2009) 1.08
Stability of an autoinhibitory interface in the structure of the tyrosine kinase ZAP-70 impacts T cell receptor response. Proc Natl Acad Sci U S A (2009) 1.04
Regulation of the Src family kinase Lck by Hsp90 and ubiquitination. Mol Cell Biol (2004) 1.04
c-Src tyrosine kinase, a critical component for 5-HT2A receptor-mediated contraction in rat aorta. J Physiol (2008) 1.02
The Abl SH2-kinase linker naturally adopts a conformation competent for SH3 domain binding. Protein Sci (2007) 1.01
Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proc Natl Acad Sci U S A (2011) 1.01
Molecular dynamics simulations show that conformational selection governs the binding preferences of imatinib for several tyrosine kinases. J Biol Chem (2010) 1.01
Src family kinases are required for prolactin induction of cell proliferation. Mol Biol Cell (2001) 0.99
Locking the active conformation of c-Src kinase through the phosphorylation of the activation loop. J Mol Biol (2013) 0.98
Quantitative relation between intermolecular and intramolecular binding of pro-rich peptides to SH3 domains. Biophys J (2006) 0.97
PAK in Alzheimer disease, Huntington disease and X-linked mental retardation. Cell Logist (2012) 0.97
A conserved salt bridge in the G loop of multiple protein kinases is important for catalysis and for in vivo Lyn function. Mol Cell (2009) 0.96
A Comparison of Three Perturbation Molecular Dynamics Methods for Modeling Conformational Transitions. J Chem Theory Comput (2009) 0.96
Migfilin interacts with Src and contributes to cell-matrix adhesion-mediated survival signaling. J Biol Chem (2009) 0.95
Abl N-terminal cap stabilization of SH3 domain dynamics. Biochemistry (2008) 0.95
Structure-guided inhibitor design expands the scope of analog-sensitive kinase technology. ACS Chem Biol (2013) 0.94
αC helix as a switch in the conformational transition of Src/CDK-like kinase domains. J Phys Chem B (2012) 0.93
Chemical genetics identifies c-Src as an activator of primitive ectoderm formation in murine embryonic stem cells. Sci Signal (2009) 0.93
Crystal structure of the Src family kinase Hck SH3-SH2 linker regulatory region supports an SH3-dominant activation mechanism. J Biol Chem (2010) 0.93
Methods for SAXS-based structure determination of biomolecular complexes. Adv Mater (2014) 0.92
Selective targeting of distinct active site nucleophiles by irreversible SRC-family kinase inhibitors. J Am Chem Soc (2012) 0.90
Reversion-induced LIM interaction with Src reveals a novel Src inactivation cycle. J Cell Biol (2009) 0.90
Structure-guided optimization of protein kinase inhibitors reverses aminoglycoside antibiotic resistance. Biochem J (2013) 0.89
Src family kinases and the MEK/ERK pathway in the regulation of myeloid differentiation and myeloid leukemogenesis. Adv Enzyme Regul (2007) 0.89
Alternative splicing modulates autoinhibition and SH3 accessibility in the Src kinase Fyn. Mol Cell Biol (2009) 0.89
p50(Cdc37) can buffer the temperature-sensitive properties of a mutant of Hck. Mol Cell Biol (2000) 0.89
Modified AutoDock for accurate docking of protein kinase inhibitors. J Comput Aided Mol Des (2002) 0.89
An inhibitor-resistant mutant of Hck protects CML cells against the antiproliferative and apoptotic effects of the broad-spectrum Src family kinase inhibitor A-419259. Oncogene (2008) 0.88
The tyrosine kinase Csk dimerizes through Its SH3 domain. PLoS One (2009) 0.88
pp60c-src associates with the SH2-containing inositol-5-phosphatase SHIP1 and is involved in its tyrosine phosphorylation downstream of alphaIIbbeta3 integrin in human platelets. Biochem J (2000) 0.87
Testing the promiscuity of commercial kinase inhibitors against the AGC kinase group using a split-luciferase screen. J Med Chem (2012) 0.87
Mutations in the catalytic loop HRD motif alter the activity and function of Drosophila Src64. PLoS One (2011) 0.87
Structural effects of clinically observed mutations in JAK2 exons 13-15: comparison with V617F and exon 12 mutations. BMC Struct Biol (2009) 0.87
Partial cooperative unfolding in proteins as observed by hydrogen exchange mass spectrometry. Int Rev Phys Chem (2013) 0.87
HIV-1 Nef interaction influences the ATP-binding site of the Src-family kinase, Hck. BMC Chem Biol (2012) 0.86
Differential sensitivity of Src-family kinases to activation by SH3 domain displacement. PLoS One (2014) 0.85
Expressing the human proteome for affinity proteomics: optimising expression of soluble protein domains and in vivo biotinylation. N Biotechnol (2011) 0.85
Crystal structure of the FLT3 kinase domain bound to the inhibitor Quizartinib (AC220). PLoS One (2015) 0.84
Interaction with the Src homology (SH3-SH2) region of the Src-family kinase Hck structures the HIV-1 Nef dimer for kinase activation and effector recruitment. J Biol Chem (2014) 0.83
Discovery of a diaminoquinoxaline benzenesulfonamide antagonist of HIV-1 Nef function using a yeast-based phenotypic screen. Retrovirology (2013) 0.83
Somatic mutations in PI3Kalpha: structural basis for enzyme activation and drug design. Biochim Biophys Acta (2009) 0.82
Prediction of specificity-determining residues for small-molecule kinase inhibitors. BMC Bioinformatics (2008) 0.82
Src family kinases play multiple roles in differentiation of trophoblasts from human term placenta. J Physiol (2006) 0.82
Tyrosine 416 is phosphorylated in the closed, repressed conformation of c-Src. PLoS One (2013) 0.82
Functional characterization and conformational analysis of the Herpesvirus saimiri Tip-C484 protein. J Mol Biol (2006) 0.82
Two amino acid residues confer different binding affinities of Abelson family kinase SRC homology 2 domains for phosphorylated cortactin. J Biol Chem (2014) 0.81
An unexpected role for the clock protein timeless in developmental apoptosis. PLoS One (2011) 0.80
The accessory factor Nef links HIV-1 to Tec/Btk kinases in an Src homology 3 domain-dependent manner. J Biol Chem (2014) 0.80
The Fyn-ADAP Axis: Cytotoxicity Versus Cytokine Production in Killer Cells. Front Immunol (2015) 0.79
Misfolding, Aggregation, and Disordered Segments in c-Abl and p53 in Human Cancer. Front Oncol (2015) 0.79
Computational study of the W260A activating mutant of Src tyrosine kinase. Protein Sci (2015) 0.78
Targeting protein kinases with selective and semipromiscuous covalent inhibitors. Methods Enzymol (2014) 0.77
Subtle Dynamic Changes Accompany Hck Activation by HIV-1 Nef and are Reversed by an Antiretroviral Kinase Inhibitor. Biochemistry (2015) 0.77
Effect of the SH3-SH2 domain linker sequence on the structure of Hck kinase. J Mol Model (2010) 0.76
An Allosteric Cross-Talk Between the Activation Loop and the ATP Binding Site Regulates the Activation of Src Kinase. Sci Rep (2016) 0.76
Bimolecular fluorescence complementation demonstrates that the c-Fes protein-tyrosine kinase forms constitutive oligomers in living cells. Biochemistry (2009) 0.76
Kinases as targets for chemical modulators: Structural aspects and their role in spermatogenesis. Spermatogenesis (2015) 0.76
Inhibition of src family kinases by a combinatorial action of 5'-AMP and small heat shock proteins, identified from the adult heart. Mol Cell Biol (1999) 0.75
Characterization of WY 14,643 and its Complex with Aldose Reductase. Sci Rep (2016) 0.75
Rapid Discovery and Structure-Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. J Med Chem (2016) 0.75
The Activation of c-Src Tyrosine Kinase: Conformational Transition Pathway and Free Energy Landscape. J Phys Chem B (2016) 0.75
A computational protocol to evaluate the effects of protein mutants in the kinase gatekeeper position on the binding of ATP substrate analogues. BMC Res Notes (2017) 0.75
The Structural Basis for Activation and Inhibition of ZAP-70 Kinase Domain. PLoS Comput Biol (2015) 0.75
Structural Characterization of Maize SIRK1 Kinase Domain Reveals an Unusual Architecture of the Activation Segment. Front Plant Sci (2017) 0.75
Crystallographic R factor refinement by molecular dynamics. Science (1987) 15.90
Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science (2000) 9.29
Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells. Immunity (1999) 7.78
Crystal structure of the Src family tyrosine kinase Hck. Nature (1997) 7.66
Multisite phosphorylation of a CDK inhibitor sets a threshold for the onset of DNA replication. Nature (2001) 7.31
Crystal structure of the eukaryotic DNA polymerase processivity factor PCNA. Cell (1994) 6.54
Three-dimensional structure of the beta subunit of E. coli DNA polymerase III holoenzyme: a sliding DNA clamp. Cell (1992) 5.77
EGF induces tyrosine phosphorylation of phospholipase C-II: a potential mechanism for EGF receptor signaling. Cell (1989) 5.68
Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: crystal structures of the complexed and peptide-free forms. Cell (1993) 5.47
Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA. Cell (1996) 5.38
Crystallographic analysis of the recognition of a nuclear localization signal by the nuclear import factor karyopherin alpha. Cell (1998) 5.27
Tyrosine kinase inhibition: an approach to drug development. Science (1995) 4.82
Molecular dynamics and protein function. Proc Natl Acad Sci U S A (2005) 4.70
The structural basis of the activation of Ras by Sos. Nature (1998) 4.50
Crystal structure of the phosphotyrosine recognition domain SH2 of v-src complexed with tyrosine-phosphorylated peptides. Nature (1992) 4.46
Novel mechanism of Wnt signalling inhibition mediated by Dickkopf-1 interaction with LRP6/Arrow. Nat Cell Biol (2001) 4.38
Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature (1997) 4.26
Inhibition of acute lymphoblastic leukaemia by a Jak-2 inhibitor. Nature (1996) 4.04
Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells. Oncogene (2001) 3.96
Crystal structure of the conserved core of HIV-1 Nef complexed with a Src family SH3 domain. Cell (1996) 3.88
Crystal structure of a tyrosine phosphorylated STAT-1 dimer bound to DNA. Cell (1998) 3.79
Three-dimensional structure of the catalytic subunit of protein serine/threonine phosphatase-1. Nature (1995) 3.77
Structure of the RCK domain from the E. coli K+ channel and demonstration of its presence in the human BK channel. Neuron (2001) 3.62
X-ray structure and refinement of carbon-monoxy (Fe II)-myoglobin at 1.5 A resolution. J Mol Biol (1986) 3.49
Crystal structure of the cytoplasmic domain of the type I TGF beta receptor in complex with FKBP12. Cell (1999) 3.47
Negative cooperativity in regulatory enzymes. Proc Natl Acad Sci U S A (1969) 3.38
Crystal structure of the nucleotide exchange factor GrpE bound to the ATPase domain of the molecular chaperone DnaK. Science (1997) 3.31
Dynamic coupling between the SH2 and SH3 domains of c-Src and Hck underlies their inactivation by C-terminal tyrosine phosphorylation. Cell (2001) 3.25
Nucleotide sequence evidence for relationship of AIDS retrovirus to lentiviruses. Nature (1985) 3.13
Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem (1989) 3.02
The TGF beta receptor activation process: an inhibitor- to substrate-binding switch. Mol Cell (2001) 2.87
Transglutaminase is essential in receptor-mediated endocytosis of alpha 2-macroglobulin and polypeptide hormones. Nature (1980) 2.82
High resolution crystal structure of a paired (Pax) class cooperative homeodomain dimer on DNA. Cell (1995) 2.78
Crystal structure of the processivity clamp loader gamma (gamma) complex of E. coli DNA polymerase III. Cell (2001) 2.68
Crystallographic analysis of the specific yet versatile recognition of distinct nuclear localization signals by karyopherin alpha. Structure (2000) 2.57
Structures of Src-family tyrosine kinases. Curr Opin Struct Biol (1997) 2.56
Mechanism of processivity clamp opening by the delta subunit wrench of the clamp loader complex of E. coli DNA polymerase III. Cell (2001) 2.39
Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors. Science (1988) 2.35
Structural basis for autoinhibition of the Ephb2 receptor tyrosine kinase by the unphosphorylated juxtamembrane region. Cell (2001) 2.31
Crystal structure of the DsbA protein required for disulphide bond formation in vivo. Nature (1993) 2.27
Thermal expansion of a protein. Biochemistry (1987) 2.25
Crystal structure of Escherichia coli thioredoxin reductase refined at 2 A resolution. Implications for a large conformational change during catalysis. J Mol Biol (1994) 2.23
Nucleotide sequence analysis of equine infectious anemia virus proviral DNA. Virology (1987) 2.19
Metal-binding sites of concanavalin A and their role in the binding of alpha-methyl d-glucopyranoside. Biochem J (1968) 2.17
Effect of anisotropy and anharmonicity on protein crystallographic refinement. An evaluation by molecular dynamics. J Mol Biol (1986) 2.16
Crystal structure of the delta' subunit of the clamp-loader complex of E. coli DNA polymerase III. Cell (1997) 2.16
Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A (1998) 2.15
Crystal structure of the atypical protein kinase domain of a TRP channel with phosphotransferase activity. Mol Cell (2001) 2.12
A single amino acid in the SH3 domain of Hck determines its high affinity and specificity in binding to HIV-1 Nef protein. EMBO J (1995) 2.10
Structural basis for the autoinhibition of calcium/calmodulin-dependent protein kinase I. Cell (1996) 2.09
The interaction of concanavalin A with methyl alpha-D-glucopyranoside. Biochim Biophys Acta (1968) 2.09
Enhanced ROS production in oncogenically transformed cells potentiates c-Jun N-terminal kinase and p38 mitogen-activated protein kinase activation and sensitization to genotoxic stress. Mol Cell Biol (2001) 2.08
Interaction of frizzled related protein (FRP) with Wnt ligands and the frizzled receptor suggests alternative mechanisms for FRP inhibition of Wnt signaling. J Biol Chem (1999) 2.05
Structural and biochemical characterization of the type III secretion chaperones CesT and SigE. Nat Struct Biol (2001) 2.04
Crystal structure of the DNA polymerase processivity factor of T4 bacteriophage. J Mol Biol (2000) 2.02
Structure of the amino-terminal protein interaction domain of STAT-4. Science (1998) 2.00
Prevention of lipopolysaccharide-induced lethal toxicity by tyrosine kinase inhibitors. Science (1994) 1.96
Mode of coupling between the beta-adrenergic receptor and adenylate cyclase in turkey erythrocytes. Biochemistry (1978) 1.87
The effect of tyrosine-specific protein phosphorylation on the assembly of adherens-type junctions. EMBO J (1992) 1.85
The crystal structure of an Eph receptor SAM domain reveals a mechanism for modular dimerization. Nat Struct Biol (1999) 1.85
Expression of the normal human sis/PDGF-2 coding sequence induces cellular transformation. Cell (1984) 1.80
Crystal structure of the Dbl and pleckstrin homology domains from the human Son of sevenless protein. Cell (1998) 1.77
Structural basis for the specific interaction of lysine-containing proline-rich peptides with the N-terminal SH3 domain of c-Crk. Structure (1995) 1.76
Half-of-the-sites reactivity and the conformational states of cytidine triphosphate synthetase. Biochemistry (1971) 1.76
Cisplatin induces PKB/Akt activation and p38(MAPK) phosphorylation of the EGF receptor. Oncogene (2006) 1.72
Tyrphostins inhibit epidermal growth factor (EGF)-receptor tyrosine kinase activity in living cells and EGF-stimulated cell proliferation. J Biol Chem (1989) 1.72
Structure-based mutagenesis reveals distinct functions for Ras switch 1 and switch 2 in Sos-catalyzed guanine nucleotide exchange. J Biol Chem (2001) 1.71
Epidermal-growth-factor-dependent activation of the src-family kinases. Eur J Biochem (1994) 1.68
Specific inhibition of insulin-like growth factor-1 and insulin receptor tyrosine kinase activity and biological function by tyrphostins. Endocrinology (1997) 1.68
Selective platelet-derived growth factor receptor kinase blockers reverse sis-transformation. Cancer Res (1994) 1.63
The role of negative cooperativity and half-of-the-sites reactivity in enzyme regulation. Curr Top Cell Regul (1976) 1.62
Challenges at the frontiers of structural biology. Trends Cell Biol (1999) 1.62
Activation of Stat3 in v-Src-transformed fibroblasts requires cooperation of Jak1 kinase activity. J Biol Chem (2000) 1.61
Flk-1 as a target for tumor growth inhibition. Cancer Res (1996) 1.56
Crystal structure of an archaebacterial DNA polymerase. Structure (1999) 1.49
Signal therapy for RAS-induced cancers in combination of AG 879 and PP1, specific inhibitors for ErbB2 and Src family kinases, that block PAK activation. Cancer J (2001) 1.49
Sequence-specific recognition of the internalization motif of the Alzheimer's amyloid precursor protein by the X11 PTB domain. EMBO J (1997) 1.48
Phosphorylation of tyrosine residues in the kinase domain and juxtamembrane region regulates the biological and catalytic activities of Eph receptors. Mol Cell Biol (2000) 1.47
Temperature dependence of the structure and dynamics of myoglobin. A simulation approach. J Mol Biol (1990) 1.46
Crystal structures of peptide complexes of the amino-terminal SH2 domain of the Syp tyrosine phosphatase. Structure (1994) 1.43
Ligand specificity and characteristics of the beta-adrenergic receptor in turkey erythrocyte plasma membranes. J Mol Biol (1975) 1.43
The influence of the proliferating cell nuclear antigen-interacting domain of p21(CIP1) on DNA synthesis catalyzed by the human and Saccharomyces cerevisiae polymerase delta holoenzymes. J Biol Chem (1997) 1.42
Adenylate cyclase activation by the beta-adrenergic receptors as a diffusion-controlled process. Biochemistry (1979) 1.42
An anti-Ras cancer potential of PP1, an inhibitor specific for Src family kinases: in vitro and in vivo studies. Cancer J (2001) 1.42
Reciprocal regulation of Hck activity by phosphorylation of Tyr(527) and Tyr(416). Effect of introducing a high affinity intramolecular SH2 ligand. J Biol Chem (2000) 1.41
Inhibition of pp60c-Src reduces Bcl-XL expression and reverses the transformed phenotype of cells overexpressing EGF and HER-2 receptors. Oncogene (1999) 1.41
The binding characteristics and number of beta-adrenergic receptors on the turkey erythrocyte. Proc Natl Acad Sci U S A (1974) 1.41
The control of adenylate cyclase by calcium in turkey erythrocyte ghosts. J Biol Chem (1975) 1.36
Characterization of Wnt-1 and Wnt-2 induced growth alterations and signaling pathways in NIH3T3 fibroblasts. Oncogene (1998) 1.36